Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
9
FDMT Quote, Financials, Valuation and Earnings
Last price:
$8.08
Seasonality move
:
0.56%
Day range:
$7.67 - $8.13
52-week range:
$2.24 - $12.34
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3,604.35x
P/B ratio:
1.25x
Volume:
613.9K
Avg. volume:
1M
1-year change:
39.41%
Market cap:
$462.8M
Revenue:
$37K
EPS (TTM):
-$3.94
Analysts' Opinion
-
Consensus Rating4D Molecular Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $33.11, 4D Molecular Therapeutics, Inc. has an estimated upside of 308.78% from its current price of $8.10.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $17.00 representing 100% downside risk from its current price of $8.10.
Fair Value
-
According to the consensus of 9 analysts, 4D Molecular Therapeutics, Inc. has 308.78% upside to fair value with a price target of $33.11 per share.
FDMT vs. S&P 500
-
Over the past 5 trading days, 4D Molecular Therapeutics, Inc. has underperformed the S&P 500 by -13.29% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
4D Molecular Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
4D Molecular Therapeutics, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter 4D Molecular Therapeutics, Inc. reported revenues of $90K.
Earnings Growth
-
4D Molecular Therapeutics, Inc. earnings have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter 4D Molecular Therapeutics, Inc. reported earnings per share of -$1.01.
Enterprise value:
180M
EV / Invested capital:
0.46x
Price / LTM sales:
3,604.35x
EV / EBIT:
--
EV / Revenue:
1,499.95x
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
-0.97x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$7.3M
Return On Assets:
-40.57%
Net Income Margin (TTM):
-174314.17%
Return On Equity:
-45.02%
Return On Invested Capital:
-42.83%
Operating Margin:
-67983.33%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $22M | $20.2M | $120K | $3K | $90K | |
| Gross Profit | $16.4M | $13.9M | -$7.3M | -$1.7M | -$1.9M | |
| Operating Income | -$104.9M | -$145.7M | -$230.4M | -$51.1M | -$61.2M | |
| EBITDA | -$99.3M | -$139.4M | -$223M | -$49.4M | -$59.2M | |
| Diluted EPS | -$2.73 | -$2.32 | -$3.94 | -$0.79 | -$1.01 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $165.7M | $232.5M | $328.2M | $510.8M | $312.4M | |
| Total Assets | $240.6M | $280.2M | $361.6M | $604M | $424M | |
| Current Liabilities | $11.4M | $13.6M | $18.2M | $29.5M | $37.1M | |
| Total Liabilities | $16.5M | $28.7M | $31.7M | $51.1M | $55M | |
| Total Equity | $224.1M | $251.4M | $329.9M | $552.9M | $369M | |
| Total Debt | -- | $13.9M | $12M | $19.7M | $16.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$73.4M | -- | -$183.5M | -$29.4M | -$46.5M | |
| Cash From Investing | $86.6M | -- | $42.9M | $27.3M | $17.8M | |
| Cash From Financing | $154.1M | -- | $1.6M | $568K | $116K | |
| Free Cash Flow | -$76.7M | -- | -$185.1M | -$31.2M | -$46.4M | |
FDMT
Sector
Market Cap
$462.8M
$28M
Price % of 52-Week High
65.64%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
-0.81%
-1.54%
1-Year Price Total Return
39.42%
-17.48%
Beta (5-Year)
--
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$9.59
200-day SMA
Buy
Level
$6.34
Bollinger Bands (100)
Sell
Level
6.95 - 10.87
Chaikin Money Flow
Sell
Level
-3.8M
20-day SMA
Sell
Level
$10.33
Relative Strength Index (RSI14)
Sell
Level
34.96
ADX Line
Sell
Level
17.69
Williams %R
Buy
Level
-89.6828
50-day SMA
Sell
Level
$10.60
MACD (12, 26)
Sell
Level
-0.48
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
15M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.3979)
Sell
CA Score
(Annual)
Level (-0.4688)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (3.7086)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.
Stock Forecast FAQ
In the current month, FDMT has received 7 Buy ratings 2 Hold ratings, and 0 Sell ratings. The FDMT average analyst price target in the past 3 months is $33.11.
-
Where Will 4D Molecular Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that 4D Molecular Therapeutics, Inc. share price will rise to $33.11 per share over the next 12 months.
-
What Do Analysts Say About 4D Molecular Therapeutics, Inc.?
Analysts are divided on their view about 4D Molecular Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that 4D Molecular Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $17.00.
-
What Is 4D Molecular Therapeutics, Inc.'s Price Target?
The price target for 4D Molecular Therapeutics, Inc. over the next 1-year time period is forecast to be $33.11 according to 9 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is FDMT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for 4D Molecular Therapeutics, Inc. is a Buy. 7 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of FDMT?
You can purchase shares of 4D Molecular Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase 4D Molecular Therapeutics, Inc. shares.
-
What Is The 4D Molecular Therapeutics, Inc. Share Price Today?
4D Molecular Therapeutics, Inc. was last trading at $8.08 per share. This represents the most recent stock quote for 4D Molecular Therapeutics, Inc.. Yesterday, 4D Molecular Therapeutics, Inc. closed at $8.10 per share.
-
How To Buy 4D Molecular Therapeutics, Inc. Stock Online?
In order to purchase 4D Molecular Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get FDMT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
FDMT
Sector
P/E ratio
--
23.89x
PEG ratio
-0.03x
-0.01x
P/B ratio
1.25x
1.82x
Price / LTM sales
3,604.35x
1.60x
Growth Metrics
FDMT
Sector
Revenue growth
2900%
4.62%
Earnings growth
-28.41%
10.88%
Revenue (5-year growth)
-64.94%
6.5%
Earnings forecast
-$0.98
-$0.21
Profitability
FDMT
Sector
Profitability FY 2024
-$6.7M
$3.5M
Return on invested capital
-42.83%
-31.77%
Return on assets
-40.57%
-27.96%
Return on equity
-45.02%
-37.63%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Feb
27
Estimated Next Earnings Date
Feb
9
Balance Sheet
FDMT
Sector
Total cash
$305.1M
$26.3M
Short term investments
$275.5M
$25.7M
Total assets
$560.4M
$78M
Long term debt
$16.6M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
